Valeant to acquire Ortho Dermatologics

Jul 16 2011NewsGuard 100/100 Score
Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that Valeant's subsidiaries, Valeant Pharmaceuticals North America LLC (VPNA) and Valeant International (Barbados) SRL (VIB), have signed an agreement to acquire the assets of the Ortho Dermatologics division of Janssen Pharmaceuticals, Inc. Valeant will pay Janssen $345 million for the assets, which includes prescription brands RETIN-A MICRO®, ERTACZO®, and RENOVA®. Total revenue for the product portfolio was approximately $150 million in 2010. The transaction is subject to certain closing conditions and regulatory approvals and is expected to be accretive in 2011.

"With the combination of this transaction and other recently announced transactions, Valeant is well on its way to being one of the leading companies in dermatology," stated J. Michael Pearson, chairman and chief executive officer. "We believe that dermatology remains an attractive therapeutic area for Valeant and we are pleased to able to add another strong franchise to our growing operations."

Source:

VALEANT PHARMACEUTICALS INTERNATIONAL, INC.

Posted in: Business / Finance

Tags: , , ,

Comments (0)

Suggested Reading

Link between COVID-19 and long-term risk of autoimmune and autoinflammatory connective tissue disorders
Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care
Obesity crisis in the U.S. expected to worsen by 2050
Teledermoscopy offers reliable skin cancer diagnosis
Study shows how a single defective BRCA1 gene accelerates cancer development
Healthy lifestyle choices can offset genetic risk for brain diseases
Early RSV vaccination in pregnancy provides best protection for newborns
Study links tanning bed use to rising melanoma rates in New England

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Study uncovers diversity of cancer-associated fibroblasts in skin cancer